On June 12, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for adults with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin after surgery, and then as a single agent.
Next CPS. < 1
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
26.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $381.6M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 27.0¢ | 25.8¢ | $942.0K | 3.538M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 139069 | 26.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.5¢ | 315950 | 5 |
View Market Depth
| Last trade - 16.10pm 28/07/2025 (20 minute delay) ? |
| IMM (ASX) Chart |